CS
AXDX

Cannell & Spears’s Accelerate Diagnostics AXDX Stock Holding History

Cannell & Spears’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-114,523
Closed -$80.3K – 397
2025
Q1 		$80.3K Hold
114,523
– – ﹤0.01% 381
2024
Q4 		$137K Hold
114,523
– – ﹤0.01% 380
2024
Q3 		$196K Hold
114,523
– – ﹤0.01% 388
2024
Q2 		$134K Sell
114,523
-167
-0.1% -$174 ﹤0.01% 354
2024
Q1 		$114K Buy
+114,690
New +$181K ﹤0.01% 370

Other funds holding AXDX

BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Cannell & Spears's AXDX Position: Q2 2025 in Review

Cannell & Spears sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 114,523 shares — an estimated $80.3K sold.

Cannell & Spears first reported a position in AXDX in Q1 2024 and held it in 5 quarters. The position peaked at $196K in Q3 2024. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

  • Cannell & Spears reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Cannell & Spears sold 114,523 Accelerate Diagnostics shares in Q2 2025, an estimated $80.3K.
  • Cannell & Spears first reported a position in Accelerate Diagnostics in Q1 2024 and held it in 5 quarters.
  • Cannell & Spears's Accelerate Diagnostics position peaked at $196K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Cannell & Spears's 13F filing for Q2 2025, filed 14 Aug 2025.